Valuation: GI Dynamics, Inc.

Market Cap 440K 386K 358K 329K 623K 42.16M 635K 4.26M 1.67M 20.7M 1.65M 1.62M 71.5M P/E 2019
-1.12x
P/E 2020 -0.03x
Enterprise Value 3.28M 2.88M 2.66M 2.45M 4.64M 314M 4.73M 31.75M 12.45M 154M 12.31M 12.05M 532M EV / Sales 2019
-
EV / Sales 2020 -
Free-Float
-
Yield 2019 *
-
Yield 2020 -
Manager TitleAgeSince
Chief Executive Officer - 05/08/2025
Director of Finance/CFO 57 01/08/2025
Chief Tech/Sci/R&D Officer - 01/04/2023
Director TitleAgeSince
Chairman 67 21/10/2020
Director/Board Member 69 01/10/2023
Director/Board Member - 20/10/2020
Date Insider Type Main position Quantity % Market Cap.
28/01/21Free

Chief Executive Officer

11,075,869 3.8998%
28/01/21Free

Chairman

1,384,483 0.4875%

Financials

2019 2020
Net sales - -
Net income -17.33M -15.2M -14.08M -12.96M -24.51M -1.66B -24.98M -168M -65.82M -815M -65.09M -63.66M -2.81B -11.14M -9.77M -9.05M -8.32M -15.74M -1.07B -16.05M -108M -42.29M -523M -41.82M -40.9M -1.81B
Net Debt 2.89M 2.53M 2.35M 2.16M 4.08M 276M 4.16M 27.95M 10.96M 136M 10.84M 10.6M 469M 2.84M 2.49M 2.31M 2.12M 4.01M 272M 4.09M 27.49M 10.78M 133M 10.66M 10.43M 461M
Logo GI Dynamics, Inc.
GI Dynamics, Inc. is a medical device company. The Company designs and applies device and disease management solutions for the treatment of metabolic disease. The Company designs, develops, manufactures and markets medical devices for non-surgical approaches to treat type II diabetes and obesity. The Company's product, EndoBarrier, is an endoscopically-delivered device therapy, which is approved for the treatment of obese type II diabetes with body mass index (BMI) greater than or equal to 30 kilogram/square meter (kg/m2), or obese patients with BMI greater than or equal to 30 kg/m2 with greater than or equal to one comorbidities, or obese patients with BMI over 35 kg/m2. EndoBarrier is an incision-free, non-anatomy altering solution designed to specifically mimic the duodenal-jejunal exclusion created by gastric bypass surgery.
Employees
-
Sector
-
  1. Stock Market
  2. Stocks
  3. GIDYL Stock